Mayo Clinic and Mayo Medical Laboratories have signed a collaboration agreement with bioTheranostics, a leading provider of molecular diagnostics solutions for cancer. Through the agreement, Mayo Clinic and Mayo Medical Laboratories will offer bioTheranostics’ molecular cancer classification test, as part of its surgical pathology consultations, to aid in the management of patients with metastatic cancer.

The CancerTYPE ID test will be available to Mayo Clinic physicians and patients at its campuses in the Midwest, Arizona and Florida, as well as to more than 5,000 hospitals around the world served by Mayo Medical Laboratories.

CancerTYPE ID, an industry-leading molecular cancer classifier, predicts tumor type in patients with metastatic cancers, which affect more than 400,000 patients in the United States each year and are among the most difficult to diagnose and treat. The CancerTYPE ID test is supported by significant clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification and impact on patient outcomes.